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Objectives: Papillary thyroid cancer (PTC) is increasing in incidence. Fine needle aspiration is the gold standard for
diagnosis, but results can be indeterminate. Identifying tissue and serum biomarkers, like microRNA, is therefore desirable.
We sought to identify miRNA that is differentially expressed in the serum of patients with PTC.
Methods: Serum miRNA was quantified in 31 female thyroidectomy patients: 13 with benign disease and 18 with PTC.
qPCR results were compared for significant fold-changes in 175 miRNAs, against a pooled control.
Results: 128 miRNA qualified for analysis. There were identifiable fold-changes in miRNA levels between benign and
control, and between PTC and control. There were statistically significant fold changes in the level of four miRNAs between
benign and PTC: hsa-miR-146a-5p and hsa-miR-199b-3p were down-regulated, while hsa-let7b-5p and hsa-miR-10a-5p
were up-regulated.
Conclusions: MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to
aid in thyroid cancer diagnosis.
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Papillary thyroid carcinoma (PTC) accounts for up to 90 %
of thyroid carcinomas, yet distinguishing carcinoma from
benign thyroid conditions such as follicular adenomas,
cysts and goiter can be difficult [1]. Thirty percent of fine
needle aspirate specimens from thyroid nodules are inde-
terminate, and up to 75 % of patients undergo a hemithyr-
oidectomy for benign disease unnecessarily [2–5]. As the
incidence of PTC increases, along with the detection of in-
cidental thyroid nodules on CT and ultrasound, research
into the development of more sophisticated means of diag-
nosis is needed.
Recent research on the development of such diagnos-
tic tools has focused on determining thyroid carcinoma
gene expression profiles to identify markers of benign
or malignant pathology [6]. Such markers, traditionally* Correspondence: rama.singh@nrc-cnrc.gc.ca
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article, unless otherwise stated.tested in tumor tissue, have been used to stratify indeter-
minate fine needle aspiration results to those more likely
to be PTC versus benign nodules. Examples of potential
markers that appear to be consistently up-regulated in
PTC tissue samples are chitinase 3 like-1 (YKL-40),
galectin-3 (Gal-3), cytokeratin 19 (CK19), tissue inhibitor of
metalloproteinases-1 (TIMP-1) and angiopoetin-1 (Ang −1)
[7–10].
An alternative to tumor tissue sampling is serum-based
diagnostic testing. Serum testing would potentially allow
for minimally invasive, safe and repeatable diagnosis,
requiring less technical skill for collection. Although the
feasibility of potential blood-based diagnostic testing has
been shown [11], no biomarkers have been identified that
reliably reflect elevated tumor tissue levels.
MicroRNAs (miRNAs) are non-coding RNA molecules
involved in the regulation of gene expression [12]. miRNAs
bind to messenger RNA (mRNA) and promote their deg-
radation or prevent their translation into proteins. Over
2000 miRNA have been identified in the human genome,cle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Sample selection
# of samples Female Tumor >1 cm Passed hemolysis
Benign 118 87 19 13
PTC 87 50 26 18
Control 3 - - 3
Serum sample collection. Control samples came from a commercially available
pooled serum sample of 20 healthy individuals
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miRNA was incidentally identified in 1993; however, its
function as a positive and negative bioregulator was not
recognized until the early 2000s [14, 15]. Deregulation of
miRNA has been associated with a number of diseases,
including malignancies such as chronic lymphocytic
leukemia, colon cancer, glioblastoma and astrocytoma
[16–19]. Traditionally, miRNAs have been detected in
tissue specimens; however, recent studies have also
shown that miRNAs remains relatively stable and
detectable in blood samples [20, 21].
Numerous independent studies have identified miRNA
expression profiles in differentiated thyroid carcinoma
tissue, suggesting they may play a role in the development
and progression of this carcinoma. miRNA profiles identi-
fied in thyroid cancer have included miRNA-221, −222
and -181b [22, 23]. It is possible that these unique miRNA
may allow for improved diagnosis, prognosis and monitor-
ing response to treatment in thyroid carcinoma.
The objective of this study was to identify potential
miRNA serum markers in patients with PTC. We
hypothesized that, given the stability of miRNA in
serum compared to traditional biomarkers, patients
with PTC would show a measureable change in the




This study was approved by the Capital Health Research
Ethics Board and informed consent was obtained from
all participants.
Blood samples (approximately 15 mL) were collected
in EDTA tubes from patients at the time of intravenous
catheter placement in the operating room, prior to the
administration of any anesthetic. A dedicated research
nurse prepared serum samples from whole blood by
centrifugation to separate serum from other blood com-
ponents. Serum was aliquoted into 1.5 mL Eppendorf
tubes, which were de-identified, barcoded and stored at
−80 °C for future use. This process generated a biobank
of 205 samples. From these, 45 samples (26 PTC and 19
benign) were randomly selected from female patients
with thyroid masses greater than 1 cm. Separate RNA ex-
tractions were performed on three aliquots of a commer-
cially available serum samples from a pool of twenty
healthy individuals (Precision Biologics, Dartmouth, NS,
Canada) for use as controls. These samples were screened
for the presence of hemolyzed red cells using the Nano-
Drop™ 1000 spectrophotometer (NanoDrop Products,
Wilmington, DE, USA) to detect optical density at
415 nm. Samples with evidence of hemolysis were
excluded prior to further analysis, leaving 31 samples (13
benign, 18 PTC) (Table 1).RNA isolation
Total RNA was extracted from 200 μL serum using the
miRNeasy® Mini Kit (Qiagen, Mississauga, ON, Canada)
as described by the manufacturer. A mixture containing
1.25 μg/mL of MS2 bacteriophage RNA, and RNA spike-
ins was added to the serum. RNA was purified on an
RNeasy® Mini spin column (Qiagen), eluted in 50 μL of
RNase-free water, and stored at −80 °C.
Sample quality control using spike-ins
To ensure that the quality of the input RNA was sufficiently
high for effective reverse transcription (RT), cDNA synt-
hesis and amplification, two types of RNA spike-ins were
used. RNA isolation controls (UniSp2 and UniSp4) were
added to the sample prior to purification and used to detect
differences in extraction efficiency and the presence of in-
hibitors. The cDNA synthesis control (UniSp6) was added
in the RT reaction to evaluate cDNA synthesis.
Reverse Transcription (RT) and RT-qPCR
For quality assessment, qPCR assays for miRNA-103, −191,
−23a, −30c, and −451 were performed. These miRNAs are
expressed at a predictable level in the majority of sample
types and are used to evaluate baseline miRNA content in
the samples. A second hemolysis test was performed at this
time using two of these microRNA: miR-451, which is
increased in hemolyzed red blood cells compared to
miR-23a, which is relatively stable in serum and plasma.
A difference in Ct values (miR-23a minus miR-451) <8.0
qualified samples for analysis. Negative controls excluding
template from the RT reaction were performed and pro-
filed with the samples. Total RNA (2 μL) was reverse tran-
scribed in 10 μL reactions using the miRCURY LNA™
Universal RT microRNA PCR, Polyadenylation and cDNA
synthesis kit (Exiqon, Woburn, MA, USA). Each RT was
performed in duplicate, including an artificial RNA spike-
in (UniSp6). cDNA was diluted 50-fold and assayed in
10 μL qPCR reactions according to the protocol for miR-
CURY LNA™ Universal RT microRNA PCR (Exiqon).
miRNAs were profiled using the microRNA Ready-to-Use
PCR human serum/plasma panel containing 175 miRNAs
plus controls (Exiqon). 5 μL RNA was reverse transcribed in
25 μL reactions and assayed as described above. Each micro-
RNA was assayed once by qPCR and negative controls ex-
cluding template from the RT reaction were included. PCR
was performed in a LightCycler® 480 Real-Time PCR System
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plates. The amplification curves were analyzed using
the Roche LC software, both for determination of expres-
sion values (2nd derivative Ct method) and for melting
curve analysis.Data analysis and statistics
The raw data was extracted from the LightCycler 480 soft-
ware. For quality control samples, an average Ct was calcu-
lated for the duplicate RTs, and evaluation of expression
levels was performed based on raw Ct-values. The amplifi-
cation efficiency was calculated using algorithms similar to
the LinReg software [24]. All assays were inspected for dis-
tinct melting curves to ensure that the Tm was within the
known specifications for the assay.
Statistics (limma expression analysis, including t-tests and
false-discovery rates) were done on the R platform using
the HTqPCR package [25]. Features where values were
missing in more than 50 % of samples from any group
(PTC, benign, control) and features where the negative
controls were within 5 Ct values of the experimental Ct
values were removed from the analysis. Data for micro-
RNAs that were present in all 31 samples were normalized
using norm rank-invariant normalization because it yielded
the lowest standard deviations in the control replicates. For
differential expression analysis, features with standard devi-
ation >0.5 in the control group were removed. Random for-
est analysis was performed in the R platform using the
random Forest package [26] and the ROCR package [27].
Gene targets for differentially expressed microRNAs were
identified using a microRNA target prediction and anno-
tation database (mirDB) using a prediction score of ≥80
(www.mirDB.org).Results
The consistent levels of all assays using RNA spike-ins
(Uni-Sp2, Uni-Sp4 and Uni-Sp6) show that the RNA ex-
traction as well as RT efficiency was similar for all sam-
ples, and that both RT and qPCR were successful. The
baseline level, which is derived from the no-template control
RT reaction, also shows that none of the samples contain
inhibitors. Quality assessment of all positive and negative
controls using qPCR assays for the commonly expressed
miR-103, −191, −23a, −30c, and −451 showed Ct values be-
tween 22–24 for the positive control and ~40 for the nega-
tive control, indicating that the RT reaction worked well.
The expression levels for all of the tested samples for these
miRNAs were comparable to each other and to what is seen
for other samples of similar types. Furthermore, the differ-
ence in Ct between miR-23a and miR-451 are 8.0 or lower
in all samples, indicating minimal signs of hemolysis. Based
on these quality control data we proceeded with the miR-
panel profiling of all passed samples.On average, 136 miRNAs were detected per sample and
128 miRNAs qualified for analysis, of which 64 were de-
tected in all 31 samples profiled. After rank invariant
normalization followed by Random Forest, t-Test and limma
statistical analyses, two miRNAs (hsa-miR-150-5p and hsa-
miR-342-3p) were down-regulated and two (hsa-let7b-5p
and hsa-miR-191-5p) were up-regulated in benign vs.
control samples (Fig. 1a; p < 0.001, FDR <5 %). For PTC vs.
control samples, one additional microRNA (hsa-miR-146a-
5p) was down-regulated and one additional microRNA
was up-regulated (hsa-miR-93-5p) (Fig. 1b; p < 0.001, FDR
<1 %). Importantly, between PTC and benign samples,
there was statistically significant down-regulation of hsa-
miR-146a-5p and hsa-miR-199b-3p, and up-regulation of
hsa-let7b-5p and hsa-miR-10a-5p (Fig. 1c, p < 0.05), al-
though the false discovery rate was high (50 %) in this
comparison. Random Forest analysis produced a classifier
consisting of 11 microRNAs (Fig. 2a), of which miRNAs
hsa-miR-10a-5p, hsa-miR-146a-5p and hsa-miR-199b-3p
were the most informative. Using this classifier, an Area
Under the Curve (AUC) of 0.851 was obtained (Fig. 2b).
Results of the limma and t-Test analysis are shown in
Table 2.
We performed additional statistical testing by adjusting
the p-values for multiple comparisons. The miRNA differ-
ences between control and benign samples were statisti-
cally significant (adjusted p < 0.05 for all miRNA), as were
the comparison between PTC and control. When this
additional statistical analysis was performed, the difference
in miRNA between benign and malignant miRNA was no
longer significant (p > 0.05).
By searching miRDB with the 11 microRNAs in the
classifier, 186 unique gene targets were identified. These
targets were mostly associated with metabolic process
(GO:0008152, 100 targets), cellular process (GO:0009987,
70 targets) and cell communication (GO:0007154, 54
targets) (Fig. 3). Six microRNAs were down-regulated
(hsa-miR-146a-5p, −199-3p, −376a-3p, 339-5p, 28-3p, and
let-7d-3p), which would result in enhanced expression of
the target genes. Five microRNAs were up-regulated (hsa-
miR-375, −10b-5p, −10a-5p, −505-3p, and -let7b -5p),
which would result in repression of the target genes.Discussion
This study identified that the serum of patients with
benign thyroid tumors showed statistically significant
down-regulation of miR-150-5p and miR-342-3p, and
up-regulation of miR-let7b-5p and miR-191-5p com-
pared to controls. The serum of patients with PTC also
showed deregulation of these miRNA, with additional
down-regulation of miR-146a-5p and up-regulation of
miR-93-5p. Most importantly, there was statistically
significant down-regulation of miR-146a-5p and miR-
Fig. 1 (See legend on next page.)
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Fig. 1 a Fold change in benign vs. control samples. Significant fold-changes were demonstrated in expression of four miRNAs between benign
and control samples. b Fold change in PTC vs. control samples. Significant fold changes were demonstrated in expression of six miRNAs between
PTC and control serum. Four of these were common to the benign vs. PTC comparison. c Fold change in PTC vs. benign samples. Statistically significant
up-regulation of hsa-miR-10a-5p and hsa-let-7b-5p was seen between the serum of PTC vs. Benign patients, and statistically significant down-regulation of
hsa-miR-146a-5p and hsa-miR-199b-3p. MicroRNAs hsa-miR-10-5p, hsa-miR-146a-5p and has-miR-199b-3 were also the most important hits in the Random
Forest analysis
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when comparing PTC serum to that of patients with
benign tumors using limma and t-tests. These are the
standard tests used in miRNA literature. Unfortunately,
these differences between miRNA between benign and
PTC patients did not reach significance with the addition
of adjusted p-value for multiple comparators.
The differences in expression levels between the con-
trol group and both the benign and PTC groups were
the greatest, with average fold changes of 3.5 and 3.0
respectively. However, the average fold change between
miRNAs that were differentially regulated between the
patients with PTC and those with benign thyroid tumors
was only 1.5. The practical impact of this modest differ-
ence is a relatively high false discovery rate of 50 %. In
other words, two of the four miRNA are likely false posi-
tives. Therefore, this panel of miRNAs would require
further validation in an independent cohort of patients.
Random Forest plots are used for classification and
regression to create predictive models for the variable im-
portance of large numbers of variables. A perfect predictor
would have an area under the curve (AUC) of 1, whereas a
predictor with an AUC of 0.5 has a predictive value no
better than chance. The AUC in the Random Forest plot in
PTC versus benign using a set of the 11 most informative
miRNA was 0.851. These miRNA target genes were con-
firmed to be involved in metabolic and cellular processes
and cell communication (Fig. 3).
Numerous studies have identified tissue miRNAs involved
in PTC tumorigenesis. The majority of these compare PTC
tissue to normal thyroid tissue – either from comparative
controls or from adjacent “normal” thyroid tissue. He et al.
were among the first to identify up-regulation of miRNA
146b, 221 and 222 in 20 patients with PTC [28]. miRNA-
146b is closely related to miRNA-146a, which was identified
in our study. MiR-146a is a known tumor suppressor and its
down-regulation appears to enhance tumorigenesis. It plays
a role in the classical NF-κB signal transduction pathway in
PTC by modulating expression of protein kinase C epsilon
(PKCε) and Ras/Raf-1 signaling. It also targets TRAF6
(mirDB score 100) and IRAK1 (mirDB score 87), which
form part of a negative feedback loop in NF-κB signaling
[29]. Pallate et al. also identified the down-regulation of
miRNA-181b in PTC tissue, corroborating the results of
He’s group [30]. Tetzlaff et al. compared PTC tissue to
multinodular goiter using formalin fixed paraffin embeddedtissue for analysis rather than fresh frozen tissue, and iden-
tified 13 up-regulated and 26 down-regulated miRNAs, in-
cluding those stated above [31].
The let7 family of miRNA was the second group to be
identified during the early study of miRNA [32]. Let7b-5p
was up-regulated in our study, both in benign and ma-
lignant tumors, and exhibited a statistically significant
increase when they were compared. It is often signi-
ficantly up-regulated in various cancers and exerts its
effects by enhancing expression of oncogenes such as Ras,
c-Myc, cyclin D and HMG [33–35]. Elevated let-7b
expression in PTC may have a similar effect on these
genes [36–38].
The most significant limitation of our study was its small
sample size (13 benign, 18 PTC and 3 controls), limiting
our statistical power. This pilot study does have the poten-
tial to guide future research into these and other miRNAs
to aid in the diagnosis of PTC.
Our study only included the PTC subtype of thyroid car-
cinoma. Although the diagnostic accuracy for anaplastic
and medullary carcinoma is greater on cytopathology alone,
follicular carcinoma still remains in the differential
diagnosis in non-diagnostic FNA. A limited number of
studies have published data on tissue miRNAs in FTC
patients. The incidence of FTC is significantly less than
that of PTC, therefore obtaining sufficient numbers for
meaningful data analysis is more difficult [39, 40].
Although the application of tissue tumor markers such
as miRNA and gene profiling may potentially improve
diagnostic accuracy, these must be obtained by FNA
biopsy and therefore remain invasive, unpleasant and
inconvenient for patients. This study suggests miRNA in
serum is stable enough for detection, supporting previ-
ous evidence to this effect. This would potentially
provide clinicians with a novel, non-invasive method to
improve diagnostic accuracy while avoiding discomfort
to the patients. Serum miRNA for diagnosis would be
particularly useful in patients with multinodular goiter.
In these patients, there are often numerous thyroid
nodules >15 mm and it can be difficult to select which
nodules should be biopsied [41]. Serum-based testing
would allow thyroid malignancy to be identified much
more simply in these patients. A previous study suggests
Canadian wait times for thyroid surgery are inappropri-
ately long [42, 43]. Preoperative risk stratification for
malignancy will help manage the limited operative time
Fig. 2 a Random Forest analysis classifier of 11 microRNAs. The top three miRNAs in this classifier (hsa-miR-10a-5p, hsa-miR-146a-5p and hsa-miR-199b-3p)
were consistent with those identified in the limma and t-test statistics. b Random Forest Area Under the Curve. AUC using all miRNAs and the 11-miRNA
random forest classifier was 0.554 and 0.851, respectively. Red circles represent benign patients, blue represent PTC patients, filled represent
correct classification, and open represent incorrect classification
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Table 2 Limma statistics and fold change
MiRNA p-value adj. p.Value t-Test Mean target Ct Mean calibrator Ct ddCT Fold change
Benign vs. Controla
hsa-miR-150-5p <0.001 <0.001 6.2 30.35 27.79 2.6 −5.9
hsa-miR-342-3p <0.001 <0.01 4.8 32.34 30.51 1.8 −3.5
hsa-let-7b-5p <0.001 0.01 −4.0 29.92 31.36 −1.4 2.7
hsa-miR-191-5p 0.001 0.04 −3.5 31.73 32.76 −1.0 2.0
PTC vs. Controlb
hsa-let-7b-5p <0.001 <0.001 −5.6 29.40 31.36 −2.0 3.9
hsa-miR-150-5p <0.001 <0.001 5.7 30.11 27.79 2.3 −5.0
hsa-miR-146a-5p <0.001 0.02 3.7 33.49 32.21 1.3 −2.4
hsa-miR-342-3p <0.001 0.03 3.7 31.88 30.51 1.4 −2.6
hsa-miR-191-5p <0.001 0.03 −3.5 31.75 32.76 −1.0 2.0
hsa-miR-93-5p <0.001 0.03 −3.5 28.68 29.53 −0.85 1.8
PTC vs. Benignc
hsa-miR-10a-5p <0.01 0.5 −3.1 35.45 35.95 −0.50 1.4
hsa-miR-146a-5p 0.01 0.5 2.7 33.49 32.93 0.56 −1.5
hsa-miR-199b-3p 0.01 0.5 2.7 33.33 32.79 0.54 −1.5
hsa-let-7b-5p 0.02 0.5 −2.4 29.40 29.92 −0.51 1.4
Fold-changes and significance of changes by t-Test/Limma. ddCT = delta delta CT – measure of relative expression quantification (comparative cycle threshold)
Adjusted p-value accounts for multiple comparisons
aFalse discovery rate (FDR) <5 %
bFDR <1 %
cFDR <50 %
Fig. 3 Role of miRNA target genes. Categories of miRNA gene targets from miRDB (microRNA target prediction and annotation database). A prediction
score of ≥80 was required
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care for those more likely to have malignancy.
Serum-based testing in cancer is gaining in popularity
as its potential feasibility is recognized. By March 2015,
more than 10 papers on this topic had been published in
a diversity of tumor types. These include non-small cell
lung carcinoma [44, 45], hepatocellular carcinoma [46],
ovarian cancer [47], and others. Studies in thyroid can-
cer have been limited to date. A study by Yu et al. in
2012 was the first to examine serum miRNAs in PTC
and identified three that were significantly up-regulated
in Chinese patients with PTC relative to benign and con-
trol patients [48]. This study was limited in that it only
aimed to detect 5-fold-changes or more, and only looked
for those miRNA that were up-regulated in sera from pa-
tients with PTC relative to those with benign disease. A
second study in Caucasian patients identified a single
miRNA as being significantly up-regulated and one down-
regulated in PTC compared to benign sera [49]. These tar-
gets, however, were different than the miRNAs identified
in the study focusing on Chinese patients.
The previous studies have failed to tightly stratify patients
based on clinical characteristics, which can have a signifi-
cant effect on miRNA expression profiles, although this has
not universally been found to be the case [50]. Each study
has identified different miRNAs that are differentially
expressed in sera of patients with PTC. The popula-
tions have all been quite disparate from one another.
We have chosen to include exclusively female patients with
tumors >1 cm in order to more tightly control differences
in baseline miRNA profiles. Nonetheless, the differences in
miRNA expression identified between studies suggests a
need for a large-scale, tightly controlled study which would
serve as a baseline for studies in other populations with dif-
ferent clinical characteristics.
Clinical application of miRNAs may extend to disease
monitoring and prognostication. The prognosis of patients
with PTC is generally good, with a 10-year survival of 85 %
[51]. Some thyroid tumors, such as the tall cell variant, can
present aggressively. miRNA detection may identify import-
ant molecular information that may determine tumor clini-
copathological characteristics and predict aggressiveness of
disease and patients at risk of poorer outcomes, and future
studies are planned to stratify based on histological sub-
types. A previous study has already shown promise in de-
tecting serum miRNAs that may be increased in recurrent
PTC [50]. Future miRNA research may even aid in man-
agement of PTC patients, given the role of miRNA in cell
proliferation, differentiation and apoptosis.
Conclusion
This study identifies four microRNAs that exhibit statis-
tically significant changes when comparing the serum of
patients with PTC to those with benign nodules. Theseresults demonstrate the potential for serum-based miRNA
assays to improve diagnostic accuracy of PTC.
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